Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors

References

• El-Metwally SA, Abou-El-Regal MM, Eissa IH, et al. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg Chem 2021;112:104947.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer [last accessed 1 March 2020].
   Google Scholar
• El-Zahabi MA, Sakr H, El-Adl K, et al. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg Chem 2020;104:104218.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65–72.
   PubMed Web of Science ®Google Scholar
• G, Krauss N, Schönbrunner J, Cooper Biochemistry of signal transduction and regulation. Weinheim: Wiley Online Library; 2003.
   Google Scholar
• Nguyen K-SH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281–9.
   PubMed Web of Science ®Google Scholar
• Abbass EM, Khalil AK, Mohamed MM, et al. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. Bioorg Chem 2020;104:104255.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Elkamhawy A, Paik S, et al. Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino) benzenesulfonamides as carbonic anhydrase isoforms I and II inhibitors. J Enzyme Inhib Med Chem 2019;34:1457–64.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Al-Rashood ST, Al-Warhi T, et al. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies. J Enzyme Inhib Med Chem 2021;36:271–86.
   Web of Science ®Google Scholar
• Shaldam M, Eldehna WM, Nocentini A, et al. Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors. Eur J Med Chem 2021;216:113283.
   PubMed Web of Science ®Google Scholar
• Grant S. Therapeutic protein kinase inhibitors. Cell. Mol. Life Sci 2009;66:1163–77.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2–16.
   PubMed Web of Science ®Google Scholar
• Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909–14.
   PubMed Web of Science ®Google Scholar
• Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res 2015;21:2684–94.
   PubMed Web of Science ®Google Scholar
• Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261–91.
   PubMed Web of Science ®Google Scholar
• Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell 1996;85:149–58.
   PubMed Web of Science ®Google Scholar
• Huang S-M, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259–69.
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
   PubMed Web of Science ®Google Scholar
• Nicholson R, gee JM, harper M. egfR and cancer prognosis. Eur J Cancer 2001;37:9–15.
   PubMed Web of Science ®Google Scholar
• Zhang H-Q, Gong F-H, Ye J-Q, et al. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. Eur J Med Chem 2017;125:245–54.
   PubMed Web of Science ®Google Scholar
• Song Z, Huang S, Yu H, et al. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem 2017;133:329–39.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Xu H, et al. 6, 7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur J Med Chem 2018;147:77–89.
   PubMed Web of Science ®Google Scholar
• Belal A. Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors. Bioorg Chem 2015;59:124–9.
   PubMed Web of Science ®Google Scholar
• Jaiash DA, Belal A, Abdelgawad MA, Abdellatif KR. Design, synthesis and biological evaluation of new pyrroloazepines with potential and selective antitumor activity. Acta Poloniae Pharmaceutica 2016;73:359–68.
   PubMed Web of Science ®Google Scholar
• Ding L, Cao J, Lin W, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 2020;21:1960.
   PubMed Web of Science ®Google Scholar
• Belal A. 3D-pharmacophore modeling, molecular docking, and virtual screening for discovery of novel CDK4/6 selective inhibitors. Russian J Bioorg Chem 2021;47:317–33.
   Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130–46
   PubMed Web of Science ®Google Scholar
• Ahn YM, Vogeti L, Liu C-J, et al. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. Bioorg Med Chem 2007;15:702–13.
   PubMed Web of Science ®Google Scholar
• Peng C, Zeng W, Su J, et al. Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway. Oncogene 2016;35:1170–9.
   PubMed Web of Science ®Google Scholar
• Yang A-l, Wu Q, Hu Z-d, et al. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling. Toxicol Appl Pharmacol 2021;431:115739.
   PubMed Web of Science ®Google Scholar
• Joshi A, Bhojwani H, Wagal O, et al. Evaluation of benzamide-chalcone derivatives as EGFR/CDK2 inhibitor: synthesis, in-vitro inhibition, and molecular modeling studies, anti-cancer agents in medicinal chemistry (formerly current). Anti-cancer Agents Med Chem 2022;22:328–43.
   PubMed Web of Science ®Google Scholar
• Mediani L, Antoniani F, Galli V, et al. Hsp90‐mediated regulation of DYRK3 couples stress granule disassembly and growth via mTORC1 signaling. EMBO Reports 2021;22:e51740.
   PubMed Web of Science ®Google Scholar
• Wippich F, Bodenmiller B, Trajkovska MG, et al. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell 2013;152:791–805.
   PubMed Web of Science ®Google Scholar
• Papadopoli D, Pollak M, Topisirovic I. The role of GSK3 in metabolic pathway perturbations in cancer. Biochim Biophys Acta (BBA)-Mol Cell Res 2021;1868:119059.
   PubMed Web of Science ®Google Scholar
• Quintayo MA, Munro AF, Thomas J, et al. GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat 2012;136:161–8.
   PubMed Web of Science ®Google Scholar
• Patel P, Woodgett JR. Glycogen synthase kinase 3: a kinase for all pathways? Curr Top Dev Biol 2017;123:277–302.
   PubMed Web of Science ®Google Scholar
• Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs 2003;12:1395–401.
   PubMed Web of Science ®Google Scholar
• Ou S-HI. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012;83:407–21.
   PubMed Web of Science ®Google Scholar
• Walter AO, Sjin RTT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discovery 2013;3:1404–15.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non–small-cell lung cancer. J Clin Oncol 2010;28:3076–83.
   PubMed Web of Science ®Google Scholar
• Kim Y, Ko J, Cui Z, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Therap 2012;11:784–91.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wu H, Wang L, et al. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol 2014;9:1230–41.
   PubMed Web of Science ®Google Scholar
• Furet P, Caravatti G, Lydon N, et al. Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des 1995;9:465–72.
   PubMed Web of Science ®Google Scholar
• Gandin V, Ferrarese A, Dalla Via M, et al. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci Rep 2015;5:16750.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358–64.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39.
   PubMed Web of Science ®Google Scholar
• Elmetwally SA, Saied KF, Eissa IH, Elkaeed EB. Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem 2019;88:102944.
   PubMed Web of Science ®Google Scholar
• Nasser AA, Eissa IH, Oun MR, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org Biomol Chem 2020;18:7608–34.
   PubMed Web of Science ®Google Scholar
• Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Therap 1999;82:195–206.
   PubMed Web of Science ®Google Scholar
• Malki Y, Martinez J, Masurier N. 1, 3‐Diazepine: a privileged scaffold in medicinal chemistry. Med Res Rev 2021;41:2247–315.
   PubMed Web of Science ®Google Scholar
• Xu T, Zhang L, Xu S, et al. Pyrimido [4, 5‐d] pyrimidin‐4 (1H)‐one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants. Angewandte Chemie 2013;125:8545–8.
   Google Scholar
• Ibrahim M, Taghour M, Metwaly A, et al. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. Eur J Med Chem 2018;155:117–34.
   PubMed Web of Science ®Google Scholar
• Mahdy HA, Ibrahim MK, Metwaly AM, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem 2020;94:103422.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Eissa IH, Belal A, El-Sayed AA. Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5 (4 H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site. RSC Adv 2020;10:2791–811.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Metwaly AM, Belal A, et al. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. Archiv Der Pharmazie 2019;352:1900123.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Ibrahim MK, Metwaly AM, et al. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorg Chem 2021;107:104532.
   PubMed Web of Science ®Google Scholar
• Alanazi MM, Eissa IH, Alsaif NA, et al. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1760–82.
   PubMed Web of Science ®Google Scholar
• Hagras M, El Deeb MA, Elzahabi HS, et al. Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation. J Enzyme Inhib Med Chem 2021;36:640–58.
   PubMed Web of Science ®Google Scholar
• Alanazi MM, Elwan A, Alsaif NA, et al. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies. J Enzyme Inhib Med Chem 2021;36:1732–50.
   PubMed Web of Science ®Google Scholar
• Gaber AA, Bayoumi AH, El-Morsy AM, et al. Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg Chem 2018;80:375–95.
   PubMed Web of Science ®Google Scholar
• El-Moghazy SM, Hanna MM, Farag AE, Belal A. Synthesis and biological evaluation of some novel substituted pyrrolizines and pyrimidopyrrolizines as Chemotherapeutic agents. Der Chemica Sinica 2017;8(1):102–16.
   Google Scholar
• Shaaban HG. Synthesis of some heterocyclic compounds derived from 2-chloro-Np-tolylacetamide. Al-Mustansiriyah J Sci 2017;27. DOI:10.23851/mjs.v27i4.26
   Google Scholar
• Gouda AM, Abdelazeem AH, Arafa E-SA, Abdellatif KR. Design, synthesis and pharmacological evaluation of novel pyrrolizine derivatives as potential anticancer agents. Bioorg Chem 2014;53:1–7.
   PubMed Web of Science ®Google Scholar
• Khademi Z, Nikoofar K. Applications of alkyl orthoesters as valuable substrates in organic transformations, focusing on reaction media. RSC Adv 2020;10:30314–97.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. JNCI: J Natl Cancer Inst 1990;82:1107–12.
   Web of Science ®Google Scholar
• Elsayed MS, El-Araby ME, Serya RA, et al. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors. Eur J Med Chem 2013;61:122–31.
   PubMed Web of Science ®Google Scholar
• El-Helby A-GA, Ayyad RR, El-Adl K, Elkady H. Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking. Mol Divers 2019;23:283–98.
   PubMed Web of Science ®Google Scholar
• El‐Helby AGA, Ayyad RR, Zayed MF, et al. Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants. Archiv Der Pharmazie 2019;352:1800387.
   Web of Science ®Google Scholar
• Abdallah AE, Alesawy MS, Eissa SI, et al. Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. N J Chem 2021;45:16557–71.
   Web of Science ®Google Scholar
• Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a Bayesian model. J Med Chem 2004;47:4463–70.
   PubMed Web of Science ®Google Scholar
• BIOVIA, QSAR, ADMET and predictive toxicology. https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/qsar-admet-and-predictive-toxicology.html [last accessed May 2020].
   Google Scholar
• Alanazi MM, Elkady H, Alsaif NA, et al. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: design, synthesis, and in silico study. J Mol Struct 2022;1253:132220.
   Web of Science ®Google Scholar
• Alsaif NA, Taghour MS, Alanazi MM, et al. Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3', 4'-c] quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1093–114.
   PubMed Web of Science ®Google Scholar
• Alanazi MM, Elkady H, Alsaif NA, et al. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv 2021;11:30315–28.
   PubMed Web of Science ®Google Scholar
• Alsaif NA, Dahab MA, Alanazi MM, et al. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: design, molecular modeling, and synthesis. Bioorg Chem 2021;110:104807.
   PubMed Web of Science ®Google Scholar
• Abbas SE, Awadallah FM, Ibrahim NA, et al. Design, synthesis and preliminary evaluation of some novel [1, 4] diazepino [5, 6-b] pyrrolizine and 6-(2-oxopyrrolidino)-1H-pyrrolizine derivatives as anticonvulsant agents. Med. Chem. Res 2011;20:1015–23.
   Web of Science ®Google Scholar
• Nicoletti I, Migliorati G, Pagliacci M, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271–9.
   PubMed Web of Science ®Google Scholar
• Hammouda MM, Abo Elmaaty A, Nafie MS, et al. Design and synthesis of novel benzoazoninone derivatives as potential CBSIs and apoptotic inducers: In Vitro, in Vivo, molecular docking, molecular dynamics, and SAR studies. Bioorg Chem 2022;127:105995.
   Google Scholar
• Belal A, Elanany MA, Santali EY, et al. Screening a panel of topical ophthalmic medications against MMP-2 and MMP-9 to investigate their potential in keratoconus management. Molecules 2022;27:3584.
   PubMed Web of Science ®Google Scholar
• Chemical Computing Group, Molecular Operating Environment (MOE). http://www.chemcomp.com/ [last accessed May 2017].
   Google Scholar